刘志博 - 北京前沿交叉学科研究院 -

个人简介

Education and Training Experience 2014.09-2016.07 Postdoctoral Research Fellow, National Institutes of Health 2010.09-2014.09 Ph.D. Department of Chemistry, University of British Columbia 2006.09-2010.06 B.S. Department of Chemistry, Nanjing University Awards and Honours 2022, 国家杰出青年基金获得者（The National Science Fund for Distinguished Young Scholars） 2021, Best Preclinical Publication Award, the 9th World ADC Annual Meeting 2021, Ones-to-Watch, Society of Nuclear Medicine and Molecular Imaging 2020, 中国化学会青年化学奖（Young Scholar Award, Chinese Chemistry Society） 2019, 药明康德生命化学青年学者奖（WuXi Eminent Young Scholar Award, WuXi AppTech Inc.） 2019, 北京大学青年教师教学基本功大赛一等奖 2018, Fairchild Award, 18th International Congress of Neutron Capture Therapy 2018, 北京大学绿叶生物青年科学家奖 2016, Distinguished Scientist Award, NIH-CSSA Committee 2015, Michael J. Welch Postdoctoral Award, Society of Nuclear Medicine and Molecular Imaging 2015, JNM Editor’s Choice Award, Society of Nuclear Medicine and Molecular Imaging 2015, Alavi-Mandell Award, Society of Nuclear Medicine and Molecular Imaging 2014, Edward Piers Memorial Award, Edward Piers Foundation 2014, Chinese Government Award for Outstanding Abroad Students, China Scholarship Council 2014, SNMMI Travel Award, Society of Nuclear Medicine and Molecular Imaging 2013, Scholar Travel Award, 23rd American Peptide Symposium 2013, Young Investigator Award, 37th CASNMMI 2013, SRS Travel Bursary, 20th ISRS 2013, Boehringer Ingelheim Scholarship, Boehringer Ingelheim Foundation 2010, Tsang Hin-chi Academic Award, Tsang Hin-chi Foundation 2006, Silver Medal, 21th Chinese Chemistry Olympiad

研究领域

Research in the Liu group focuses on the development of novel radiopharmaceutical chemistry for cancer diagnosis and advanced radiotherapy. We seek to discover molecular structure and activity that can contribute to interdisciplinary solutions for long-standing challenges in clinics. Our lab works on synthetic organic/bioconjugate chemistry, late-stage radiolabeling, PET imaging and mechanistic studies to pursue the molecules of interest in early diagnosis, patient selection and tailored treatment. Keywords: In vivo chemistry, radiopharmaceutical chemistry, molecular imaging, neutron capture therapy, radiotherapy-activated prodrug

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Ziren Kong#, Zhu Li#, Junyi Chen#, Yixin Shi, Nan Li, Wenbin Ma, Yu Wang*, Zhi Yang*; Zhibo Liu*, A histogram of [18F]BBPA PET imaging differentiates non-neoplastic lesions from malignant brain tumors. EJNMMI Res. 2024, 14 (1). Zhu Li#, Junyi Chen#, Ziren Kong, Yixin Shi, Mengxin Xu, Bo-Shuai Mu, Nan Li, Wenbin Ma, Zhi Yang, Yu Wang*; Zhibo Liu*, A bis-boron boramino acid PET tracer for brain tumor diagnosis. Eur J Nucl Med Mol Imag. 2024, 10.1007/s00259-024-06600-5. Jialing Sun#, Junyi Chen#, Yiming Sun, Yingqin Hou, Zhibo Liu*; Hua Lu*, On the origin of the low immunogenicity and biosafety of a neutral α-helical polypeptide as an alternative to polyethylene glycol. Bioact Mater. 2024, 32, 333-343. Di Sang, Keteng Lin, Yini Yang, Guangdi Ran, Bohan Li, Chen Chen, Qi Li, Yan Ma, Lihui Lu, Xi-Yang Cui, Zhibo Liu, Sheng-Qing Lv, Minmin Luo, Qinghua Liu, Yulong Li, Eric Erquan Zhang. Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals. Cell. 2023, https://doi.org/10.1016/j.cell.2023.10.025. Mengqi Chen#, Chunhong Wang#, Xuanyu Wang, Zhiyu Tu, Zexuan Ding, Zhibo Liu*. An “AND” Logic-Gated Prodrug Micelle Locally Stimulates Antitumor Immunity. Adv Mater. 2023, https://doi.org/10.1002/adma.202307818. Qunfeng Fu#, Siyong Shen#, Pengwei Sun, Zhi Gu, Yifei Bai, Xianglin Wang, Zhibo Liu*. Bioorthogonal chemistry for prodrug activation in vivo. Chem Soc Rev. 2023, 52: 7737-7772. Hanbo Song#, Mengxin Xu#*, Jie Cai, Junyi Chen, Yu Liu, Qi Su, Zhu Li*, Zhibo Liu*. 225Ac-Labeled Antibody for Fibroblast Activation Protein-Targeted Alpha Therapy. Chemical & Biomedical Imaging. 2023, 1 (7): 628-636. Mengxin Xu#, Junyi Chen#, Pu Zhang, Jie Cai, Hanbo Song, Zhu Li*, Zhibo Liu*. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy. Eur J Nucl Med Mol Imaging. 2023, 50: 3214–3224. Yu Liu, Haocheng Tang, Tianchi Song, Mengxin Xu, Junyi Chen, Xi-Yang Cui, Yuxiang Han, Zhu Li, Zhibo Liu*. Organotrifluoroborate Enhances Tumor Targeting of Fibroblast Activation Protein Inhibitors for Targeted Radionuclide Therapy. Eur J Nucl Med Mol Imaging. 2023, 50: 2636–2646. Yaxin Shi#, Zhibin Guo#, Qiang Fu#, Xinyuan Shen, Zhongming Zhang, Wenjia Sun, Jinqiang Wang, Junliang Sun, Zizhu Zhang, Tong Liu, Zhen Gu*, Zhibo Liu*. Localized Nuclear Reaction Breaks Boron Drug Capsules Loaded with Immune Adjuvants for Cancer Immunotherapy. Nat Commun. 2023, 14: 1884. Dongban Duan#, Yi Han#, Zhiyu Tu#, Haoxuan Guo, Zizhu Zhang, Yaxin Shi, Jiyuan Li, Qi Sun, Junyi Chen, Zhu Li, Tong Liu, Daqing Cui, Zhibo Liu*. Gadolinium Neutron Capture Reaction-Induced Nucleodynamic Therapy Potentiates Antitumor Immunity. CCS Chemistry. 2023, 5(11): 2589-2602. Qi Sun#, Jiyuan Li#, Zexuan Ding, Zhibo Liu*. Radiopharmaceuticals heat anti-tumor immunity. Theranostics. 2023, 13(2): 767-786. 李嘉颢, 梁炜秋, 穆博帅, 刘志博*. 二氟甲基自由基反应及其在18F标记中的应用. 高等学校化学学报. 2022, 43(12), 20220652. Qiang Wei, Yuhxuan Lee, Weiqiu Liang, Xiaolei Chen, Bo-Shuai Mu, Xi-Yang Cui, Wangsuo Wu, Shuming Bai, Zhibo Liu*. Photocatalytic Direct Borylation of Carboxylic Acids. Nat Commun, 2022, 13: 7112. Jie Ding, Mengxin Xu, Junyi Chen, Pu Zhang, Li Huo*, Ziren Kong*, Zhibo Liu*. 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis. Mol Pharm, 2022, 19(9): 3429−3438. Zhibin Guo#, Hanyu Hong#, Yuedan Zheng, Ziyang Wang, Zexuan Ding, Qunfeng Fu, Zhibo Liu*. Radiotherapy-Induced Cleavage of Quaternary Ammonium Groups Activates Prodrugs in Tumors. Angew Chem Int Ed, 2022, 61(34): e202205014. Mengqi Chen, Chunhong Wang, Zexuan Ding, Hao Wang, Yu Wang, Zhibo Liu*. A Molecular Logic Gate for Developing “AND” Logic Probes and the Application in Hepatopathy Differentiation. ACS Central Science, 2022, 8: 837−844. Xi-Yang Cui, Yu Liu, Changlun Wang, Zihao Wen, Yichen Li, Haocheng Tang, Juan Diwu, Yuchuan Yang, Mengchao Cui, Zhibo Liu*. China's Radiopharmaceuticals on Expressway: 2014-2021. Radiochimica Acta, 2022, https://doi.org/10.1515/ract-2021-1137. Zexuan Ding, Zhibin Guo, Yuedan Zheng, Ziyang Wang, Qunfeng Fu, and Zhibo Liu*. Radiotherapy reduces N-oxides for prodrug activation in tumors. J Am Chem Soc, 2022,144(21):9458-9464. Ziren Kong #, Zhu Li #, Junyi Chen #, Wenbin Ma, Yu Wang*, Zhi Yang*, Zhibo Liu*. Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors. EJNMMI Res, 2022, 12(1):22. Jiyuan Li#, Qi Sun#, Chuanjie Lu, Han Xiao, Zhibin Guo, Dongban Duan, Zizhu Zhang, Tong Liu, Zhibo Liu*. Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun, 2022, 13: 2143. Junyi Chen, Jingfeng Wang, MengXin Xu, Xianlu Jia, Guofang Song, Zhibo Liu*. Production of positron-emitting radionuclide yttrium-86 with a computer-aided design target for positron emission tomography. Nucl Med Biol, 2022, 108-109:54-60. Junyi Chen, Mengxin Xu, Yu Liu, Dongban Duan, Yuxiang Han, Zhibo Liu*. Isolation of 212Pb from natural thorium for targeted alpha-therapy. Chin Chem Lett, 2022, 33(7):3474-3477. Ziren Kong#, Zhu Li#, Junyi Chen#, Sirui Liu, Delin Liu, Jiyuan Li, Nan Li, Wenbin Ma, Feng Feng, Yu Wang*, Zhi Yang*, Zhibo Liu*. Metabolic characteristics of [18F] fluoroboronotyrosine (FBY) PET in malignant brain tumors. Nucl Med Biol, 2022, 106-107:80-87. Pu Zhang#, Mengxin Xu#, Jie Ding, Junyi Chen, Taiping Zhang, Li Huo*, Zhibo Liu*，Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy, Eur J Nucl Med Mol Imaging, 2021, 49, 1985–1996. Huifang He, Jiyuan Li, Ping Jiang, Suqing Tian, Hao Wang, Ruitai Fan, Junqi Liu, Yuyan Yang, Zhibo Liu*, Junjie Wang*, The basis and advances in clinical application of boron neutron capture therapy, Radiat Oncol, 2021, 16(1):216. Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo, Zhibo Liu*, Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy. J Nucl Med, 2021, doi: 10.2967/jnumed.121.262533. Junyi Chen, Yinlong Lv, Feng Wang, Tianjue Zhang, Zhibo Liu*, Production and isolation of actinium-225 with a 100 MeV proton cyclotron and solid-phase extraction for targeted radiotherapy. Chemistry (HXTB), 2021, 84(11):1211-1219. Chunhong Wang, Hanyu Hong, Mengqi Chen, Zexuan Ding, Yuchen Rui, Zi-Chen Li,Zhibo Liu*, A Cationic Micelle as In Vivo Catalyst for Tumor-Localized Cleavage Chemistry. Angew Chem Int Ed, 2021,60, 19750-19758 Zhu Li#, Ziren Kong#, Junyi Chen, Jiyuan Li, Nan Li, Zhi Yang*,Yu Wang*, Zhibo Liu*, 18F-Boramino Acid PET/CT in Healthy Volunteers and Glioma Patients. Eur J Nucl Med Mol Imaging, 2021, 48(10):3113-3121. Dongban Duan, Hao Dong, Zhiyu Tu, Chunhong Wang, Qunfeng Fu, Junyi Chen, Hai-peng Zhong, Ping Du, Ling-Dong Sun, Zhibo Liu*, Desilylation Induced by Metal Fluoride Nanocrystals Enables Cleavage Chemistry In Vivo. J Am Chem Soc, 2021,143(5):2250-2255. Jingyun Ren, Mengxin Xu, Junyi Chen, Jie Ding, Peipei Wang, Li Huo*, Fang Li*, Zhibo Liu*, PET Imaging Facilitates Antibody Screening for Synergistic Radioimmunotherapy with A 177Lu-Labeled αPD-L1 Antibody. Theranostics, 2021,11(1):304-315.